Premium
Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo‐controlled trial
Author(s) -
HUSTED S. E.,
NIELSEN H. KRAEMMER,
KRUSELL L. R.,
FAERGEMAN O.
Publication year - 1989
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1989.tb01400.x
Subject(s) - medicine , myocardial infarction , placebo , incidence (geometry) , chest pain , coronary care unit , infarction , randomized controlled trial , aspirin , anesthesia , cardiology , surgery , physics , alternative medicine , pathology , optics
Husted SE, Kraemmer Nielsen H, Krusell LR, Faergeman O (Department of Internal Medicine and Cardiology, Åarhus Amtssygehus, University Hospital, Åarhus, Denmark). Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo‐controlled trial. Of 1078 patients admitted to the coronary care unit with acute chest pain, 293 who had possible acute myocardial infarction and symptoms of median 4 h duration were randomized to treatment with acetylsalicylic acid (ASA) 100 mg daily, 1000 mg daily or placebo for 3 months. During hospitalization, the combined incidence of cardiac death and non‐fatal myocardial infarction on‐treatment (withdrawals not included) was significantly lower ( P < 0.02) in the 100 mg group (7.1%) than in both the 1000 mg group (20.8%) and the placebo group (19.7%). During later time periods of treatment and at all time periods analysed according to the intention‐to‐treat principle (withdrawals included), data suggested the same trend, but differences were not statistically significant. Collagen‐induced platelet aggregation and serum thromboxane B 2 were reduced to the same degree in the two ASA groups and were normal in the placebo group. The data suggest that low‐dose ASA could be cheap and safe as first‐aid therapy in myocardial infarction suspects.